Early sepsis care often begins with an alert—not a diagnosis. While early warning systems help raise suspicion, they can also create uncertainty because the signals used to flag sepsis overlap with many other conditions.
This infographic explores how diagnostic clarity can complement early alerts, helping clinicians better distinguish true sepsis risk and prioritize urgent action.
Vanessa is a senior financial executive with over 25 years of experience assisting healthcare, technology, and consumer/retail companies scale their business. Her career reflects a demonstrated track record of building and developing high-functioning finance and accounting teams, leading corporate development, raising capital, rapidly growing revenues, building out a business intelligence function, managing investor relations, and executing M&A transactions in domestic and global markets. Vanessa has previously held six CFO role across a variety of businesses, including as the first CFO at Tempus AI (NASDAQ: TEM, $10B Mkt Cap). Prior to her CFO roles, Vanessa was a sell-side investment banker for nearly six years at William Blair. Earlier in her career, Vanessa worked in finance at Kraft Foods, as well as three tech- focused companies. She started her career as an auditor at Arthur Andersen where she provided professional services to a large public food company, as well as an auto parts manufacturer.
With more than 30 years of combined experience in clinical research as well as the Emergency Department and Critical Care settings, Meghann has established herself as a passionate advocate for patient care. Her commitment extends to the advancement of treatment options within clinical settings, demonstrating a clear dedication to improving outcomes for patients. Prior to joining Prenosis, Meghann held several notable leadership positions in the clinical research industry. She served as Vice President and Head of Operations at PanCan, Vice President and Therapeutic Area Head at Iqvia Biotech as well as Vice President of Therapeutic Area Strategy at Worldwide Clinical Trials. Meghann has successfully led several NDA/BLA submissions and approvals during her tenure in addition to advancing strategic initiatives within her respective organizations. Meghann is a Duke University Hospital nursing scholarship recipient, highlighting her academic achievements and commitment to nursing excellence.
Avi is a strategic technology leader with over two decades of R&D experience guiding Software, Firmware, Quality Assurance, and Enterprise Architecture teams. He played a pivotal role in shaping the technological landscape of multiple organizations by driving innovation and delivering clinically advanced, custom-built digital platforms. His expertise spans the development of infusion pumps, SaMD products for defibrillators, pacemakers, and diagnostic devices. Most recently, Avi led the development of AI/ML-powered, FDA-regulated healthcare solutions addressing rare diseases and dementia. With a Bachelor’s degree in Engineering and a Master’s degree in Business Management, he combines deep technical knowledge with strong business acumen to bridge innovation, strategy, and execution, helping organizations accelerate growth, transformation, and impact in the healthcare technology space.
Bill comes to Prenosis with over two decades of leadership and technical experience developing and integrating enterprise-class medical software in commercial, healthcare and government settings. While Bill has worn many hats over the years, he primarily specializes in healthcare interoperability. Bill helped launch a company that eventually became the market leader in Infection Surveillance software. Bill received his B.S. in Computer Science as well as a B.S. in Business Administration from the University of Vermont.
Jim brings a wealth of experience to our team. He played a crucial role in the commercialization of PINC AI’s Healthcare Database, working closely with pharmaceutical, device, and diagnostic companies. His background includes significant experience at Merck, where he supported the anti-infective franchise as a Medical Science Liaison and in a commercial capacity. Jim holds a Bachelor of Science in Pharmacy and a Doctor of Pharmacy from Temple University, along with a Master’s in Business Administration from Penn State University.
Mark has more than 30 years of global experience in the medical device industry. He most recently served as the President and CEO of Celleration until its acquisition by Alliqua in May 2015. Prior to this, he served as the CEO for Reshape Medical, ProVation Medical, and Survivalink, all of which resulted in successful exits. He currently sits on the Board of Directors of Minnetronix, Zipnosis, Alliqua, and Miromatrix. Mark began his career at GE Healthcare, where he worked in various roles in marketing, business development, and finance. He holds a degree in Business from the University of Southern California.
Nam Nguyen is a passionate Medical Informatics Professional, Data Product Manager, and Data Science VP with a mission to transform health data into actionable insights that improve patient outcomes. With over 15 years of experience in health data management, including Administrative Claims Data, Real World Data, and HIPAA de-identification, Nam has led initiatives in clinical decision support, quality measure R&D, NLP, data science, and the transformation of dirty health data into research-ready resources. As a former Chair of the HIMSS EHRA Privacy & Security Workgroup and a HITRUST Certified De-Identification Professional, Nam’s expertise in the compliant secondary use of health data has driven successful Real World Evidence and Life Science initiatives. Throughout his tenures at IMS Health, Practice Fusion, Allscripts, and Veradigm, Nam has overseen the iterative releases of Health Analytics Platforms, Custom Provider Directory Solutions for major health plans, and the creation of one of the largest claims-linked ambulatory EHR datasets on the market today. Nam holds an eMBA from Quantic School of Business and Technology, as well as multiple Master of Science degrees from the University of San Francisco and the University of California at Davis.
Currently advising biopharma clients in business development, strategy, and licensing and acquisition matters, Suzy’s corporate career spanned almost three decades at Abbott and AbbVie before retiring from her position as Vice President, Business Development & Acquisitions focused on Immunology. She held that role since the pharmaceutical division of Abbott was spun off to create AbbVie in January 2013. Prior to that time, Suzy was Divisional Vice President in the Pharmaceutical Licensing & Acquisitions team at Abbott and Divisional Vice President leading the Licensing & Acquisitions team for Abbott Nutrition. She held roles of increasing responsibility in Abbott’s Pharmaceutical Division’s Technology Licensing Group, in its Hospital Products Division, initially as Director, Licensing & Acquisitions, then leading the Acute Care Hospital Pharmaceutical Marketing team, and returning to the Pharmaceutical Group in 2001 to head the Scientific Assessment / Technology Licensing team. She received her A.B. in chemistry with honors from Wellesley College, her M.S. and Ph.D. degrees in chemistry from Northwestern University.
Rashid Bashir is Professor of Bioengineering, the Grainger Distinguished Chair in Engineering, and is currently the Dean of Grainger College of Engineering at the University of Illinois at Urbana-Champaign. He was a member of the core founding team for the Carle Illinois College of Medicine. He was a faculty member at Purdue University, where he started his academic career. Prior to that he spent 6 years at National Semiconductor Corporation commercializing analog and RF chip manufacturing technologies. In 2018, he received the Pritzker Distinguished Lectureship Award from BMES. He is a member of the Executive Committee on the Chan Zuckerberg Biohub Chicago. He has authored or co-authored over 300 journal papers and has been granted over 60 patents. He is a fellow of IEEE, BMES, AIMBE, APS, IAMBE, NAI, RSC, and AAAS. He is academic co-founder of Prenosis, Inc. and VedaBio, Inc. In 2023, he was elected to the National Academy of Medicine. He received his B.S. degree in Electrical Engineering from Texas Tech University and his M.S and Ph.D. in Electrical Engineering from Purdue University.
Dr. Ruoqing Zhu is an Associate Professor of Statistics at the University of Illinois at Urbana-Champaign. Dr. Zhu received his Ph.D. of Biostatistics in 2013 from the University of North Carolina at Chapel Hill and worked as a postdoctoral research associate at Yale University from 2013 to 2015 before he joined the department of Statistics at UIUC. His research interest lies in personalized medicine, reinforcement learning, random forests, survival analysis, sufficient dimension reduction, and machine learning applications in biomedical problems such as infectious diseases, nutrition health, diagnostics and cancer. He is affiliated with the Carle Illinois College of Medicine, the National Center for Supercomputing Applications and the Carl R. Woese Institute for Genomic Biology. He is currently serving as an Associate Editor at Journal of the American Statistical Association and Statistical Analysis and Data Mining.
Dave has specialized in statistical techniques for analyzing large-scale data from high-throughput biological datasets for over 11 years, and has developed accurate inference and prediction models using multiple omics datasets across varied subjects, phenotypes, modalities, and species. Dave’s broad collaborative research experience includes GWAS of pediatric autoimmune disease, eQTL studies of human heart failure, integrative genomics studies of long noncoding RNAs in cancer, and cross-species studies of the molecular roots of social behavior. He is currently an Assistant Professor of Statistics at the University of Illinois at Urbana-Champaign. Dave received a Ph.D. in Biostatistics, and A.M. and A.B. degrees in Statistics and Chemistry/Physics, respectively, all from Harvard University.
Philip A. Verhoef, MD, Ph.D is a Med Peds intensivist, caring for patients in both the adult and pediatric critical care units at Kaiser Permanente Hawaii and Kapiolani Medical Center for Women and Children in Honolulu, HI. In addition, he is an Associate Clinical Professor of Medicine at the John A. Burns School of Medicine at the University of Hawaii. Dr. Verhoef completed medical and graduate training at Case Western Reserve University, followed by residency in internal medicine and pediatrics at UCLA and subspecialty ICU fellowship training at the University of Chicago. He has led an NIH-funded research lab using mouse models and human samples and big data analysis to study the immunology of sepsis in the ICU, with his scientific work being published in Nature, JAMA, Intensive Care Medicine, Critical Care Medicine, PNAS, and AJRCCM, among others.
Dr. Pratik Sinha is a physician-scientist faculty at Washington University School of Medicine. Clinically, Pratik practices in the surgical and cardiothoracic ICUs. He runs a precision medicine research program that seeks to deliver individualised therapies to critically ill patients. His research is focused in delivering precision medicine in critical care syndromes such as sepsis and ARDS. Through innovative biological measurement systems and novel data science techniques, his research program hopes to deliver the right therapies to the right patients at the right time. His clinical training was in the U.K. and Australia and he received his Ph.D from Imperial College, London, where he received training in applied respiratory physiology and biostatistics. He completed two postdoctoral scholarships at Columbia University and UCSF.
Dr. Klauer currently is the CEO of the American Health Information Management Association. Dr. Klauer formerly served as System Chief Medical Officer for HCA Florida Ocala and West Marion Hospitals, and prior to that was the CEO of the American Osteopathic Association. Dr. Klauer served as the Chief Medical Officer, Hospital Based Services, Enterprise Chief Risk Officer, and Executive Director of the Patient Safety Organization for TeamHealth. He has been recognized by Modern Healthcare as one of the nation’s “Top 150 Most Influential Clinical Executives.” He holds the following faculty appointments: Assistant Clinical Professor at Michigan State University College of Osteopathic Medicine and Clinical Assistant Professor, Ohio University Heritage College of Osteopathic Medicine. Dr. Klauer received his Doctor of Osteopathic Medicine degree from Des Moines University College of Osteopathic Medicine and completed his residency training in Emergency Medicine at LSU Health Sciences Center, Charity Hospital New Orleans. Dr. Klauer earned his Executive JD, with honors, from Purdue Global Law School in 2011.
Maria Siambekos is a healthcare technology executive with more than 25 years of diverse business experience in Fortune 10 and VC/PE backed organizations. She has served as CEO, President, and COO of multiple growth stage Healthcare IT enterprise SaaS-based companies resulting in multiple successful exits. She has also held numerous leadership roles at GE Healthcare and Hospira in commercial, product, strategy, integration, and M&A. Maria began her career as clinical scientist at The University of Chicago and as a consultant, where she delivered a breadth of strategic, operational, and clinical technology consulting engagements for hospitals, health systems, and payers. Maria has a B.S. in Biology from Yale University and an MBA from The University of Chicago Booth School of Business.
With over $1B invested in healthcare, Julia is the Founder and Managing Partner of PACE Healthcare Capital, an early-stage investment fund focused on healthcare tech and digital health businesses in the U.S. Daughter of entrepreneurs, she is passionate about building successful businesses solving critical issues in healthcare. Before starting PACE, Julia spent over 10 years investing in healthcare private equity. She was a Director at CDPQ, Canada’s second largest pension plan with $300B of AUM, where she co-led direct healthcare PE investments in North America and LATAM. Prior to CDPQ, Julia was at Monitor Clipper Partners, a $2B mid-market PE fund investing in founder-led businesses in North America and Europe. Julia started her career at Merrill Lynch, in Leveraged Finance and Healthcare M&A. Julia holds an MPA from the Harvard Kennedy School where she was the recipient of the Marguerite Carriere fellowship and A.L. Littauer award, and a Masters in Management from ESCP Europe.
Ed served as the Chief Scientific Officer and Senior VP of Research & Development and Regulatory Affairs at Hospira for four years. Prior to that, he was the Corporate VP of Hospital Products Research & Development at Abbott Laboratories, and served in a number of leadership positions over 20 years with Abbott, primarily in Abbott’s Diagnostics Division.
Sean was previously the Executive Vice President of Malin Life Sciences Holding, a publicly traded investment company. Sean was a co-founder of Malin, which has invested approximately $500M of capital across 18 companies that include pharmaceuticals, medical devices, and healthcare services. Prior to that, he was a Senior Advisor at Evercore Partners, a leading investment-banking advisory firm. Prior to his most recent endeavors, Sean was the Head of Corporate M&A and Business Development at Abbott Laboratories. He played a leading role in a number of strategic investments, totaling an excess of $35B, along with running a number of its businesses, during his 30-year career at Abbott.
Dr. Kurtzman has over 30 years of experience as a venture capitalist, entrepreneur, board member, financier and operator. As Managing Director of Healthcare Investments at Safeguard Scientifics (NYSE:SFE), Dr. Kurtzman leveraged his medical expertise to empower businesses to enhance their products, expand their services, and identify strategic partnership opportunities. Dr. Kurtzman has realized value for companies through a series of successful IPOs, M&A and turnaround transactions—most recently Advanced BioHealing for $750 million and Eli Lilly’s acquisition of Avid Radiopharmaceuticals for up to $800 million. Dr. Kurtzman’s previous experiences include leadership roles at BioAdvance, Pluvita Corporation, Genovo, Avigen, Alverix, Crescendo Bioscience, and Gilead Sciences. Presently, Dr. Kurtzman is a lecturer in the Health Care Systems Department at the Wharton School at the University of Pennsylvania where he teaches entrepreneurship in life sciences. In addition, he is also a member of the board at several other innovative healthcare companies.
Dr. Shapiro is a Professor of Emergency Medicine at Harvard Medical School and attending physician in the Department of Emergency Medicine at Beth Israel Deaconess Medical Center. Dr. Shapiro is the Vice Chairman of Research for the Emergency Department. He received his medical degree from Temple University School of Medicine, completed an internship in transitional medicine at Cook County Hospital, followed by a residency in Emergency Medicine at the Harvard Affiliated Emergency Medicine. Dr. Shapiro has a MPH in clinical effectiveness from the Harvard School of Public Health. He has over 200 original publications, including in JAMA, New England Journal of Medicine, and PLoS One. He regularly lectures nationally and internationally on the approach to diagnosis and treatment of sepsis in the emergency department and has received multiple grants including the NIH, the DoD, and industry sponsors. As part of his research portfolio, he serves as a principal investigator and liaison with the FDA for companies seeking new indications for biomarkers and devices.
Brian has a deep technical background, focused on building and integrating clinical information systems, clinical data warehouses and clinical quality management tools for over twenty years. At Prenosis, he leads cloud, data and software engineering activities as well as hospital integration efforts. Most recently he was a Clinical Data Integration Architect at Verily Life Sciences, an Alphabet company devoted to precision health. Brian has a B.S. in Computer Science and an MBA in Technology Management from Westminster University as well as an M.S. in Biomedical Informatics from the University of Utah.
Robin is a highly accomplished executive with extensive clinical and commercial experience in the acute care setting. She has over two decades of experience in advancing technology in hospitals. As a clinically oriented executive, she is passionate about helping clinicians gain timely, accurate access to the information they need to provide top quality patient care. Before joining Prenosis, Carver served as a Vice President at Premier Inc. She received a M.S. in Nursing from East Carolina University and a B.S in nursing from the University of North Carolina at Chapel Hill.
Carlos is an innovator and multidisciplinary problem solver focused on biotechnology, clinical research and product development. Carlos has lead the building of the Prenosis platform, the world’s most comprehensive system for understanding acute immune response. Previously he worked in medical devices and diagnostics in a wide range of disciplines aimed at converting ideas into solutions, including several successful FDA clearances and market launches of IVD devices. Carlos studied aeronautical engineering at the Polytechnic University of Madrid and earned his M.S. in Mechanical Engineering from the University of Illinois at Chicago.
Angela is a seasoned CFO with over 20 years experience leading organizations in the biotechnology industry and start-up environment. Previously, she held the position of CFO for Sony Biotechnology after negotiating the acquisition of the start-up company by Sony Corporation on 2009. Angela began her career in public accounting with PwC. She is a C.P.A. with a bachelor’s degree in Public Accounting from Illinois Wesleyan University and an M.B.A. from Warrington College of Business at the University of Florida.
Bobby has led the company from inception, driving company vision, building the team, securing clinical and strategic partnerships, and raising funds. He has more than a decade of experience in the research and development of early screening technologies for debilitating diseases with a deep understanding of clinical issues. For several years, Bobby has worked intimately with a wide variety of clinical and administrative hospital personnel to comprehensively understand how technology can address the most critical issues they face. He received a Ph.D. in electrical engineering from the University of Illinois at Urbana-Champaign, an M.S. in electrical engineering from the University of California, Irvine, and B.S. degrees in computer engineering and electrical engineering from the University of California, Irvine.
